Research use only. The information below is provided for licensed researchers and educational reference. Retatrutide is an investigational compound and is not approved for human consumption in Canada or elsewhere.
Retatrutide Canada searches have climbed faster than almost any other research compound this year, and it is easy to see why. Retatrutide is a first-in-class triple hormone receptor agonist whose Phase 3 data, released through late 2025 and 2026, has pushed Canadian research interest to record highs. This guide explains what retatrutide is, how it compares to earlier peptides like tirzepatide and semaglutide, what the latest trial data shows, and how research teams across Canada source high-purity, third-party-tested material.
What Is Retatrutide?
Retatrutide (development code LY-3437943) is an investigational peptide developed by Eli Lilly. Unlike single- or dual-pathway compounds, it is a GIP, GLP-1, and glucagon triple receptor agonist, meaning it simultaneously activates the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.
That third receptor, glucagon, is what sets retatrutide apart from tirzepatide (a dual GIP/GLP-1 agonist) and semaglutide (a single GLP-1 agonist). Glucagon receptor activity is associated with increased energy expenditure, which researchers believe contributes to the unusually large effect sizes observed in trials.
Is Retatrutide Available in Canada?
Retatrutide is not approved by Health Canada for clinical or human use. It remains an investigational compound moving through Eli Lilly’s Phase 3 TRIUMPH clinical program. It is not available by prescription and cannot legally be marketed for human consumption.
What is available to Canadian researchers is retatrutide supplied strictly for laboratory and research applications, sold as a lyophilized (freeze-dried) powder in labeled vials, clearly designated research use only. For this material, purity and third-party verification matter far more than anything else, because unverified powder is the single biggest variable in reproducible research. Canadian labs that need documented material typically source third-party tested Retatrutide from Anglo Peptides, where every batch ships with a certificate of analysis confirming 99%+ purity.
Retatrutide 2026 Phase 3 Results: What the Data Shows
The TRIUMPH Phase 3 program is what turned retatrutide from a promising early-stage molecule into headline news. Key readouts include:
- TRIUMPH-1 (obesity): Participants on the 12 mg weekly dose achieved an average body-weight reduction of roughly 28.3% at 80 weeks and up to 30.3% at 104 weeks, figures that approach outcomes previously associated only with bariatric surgery.
- TRIUMPH-4: A mean body-weight reduction of approximately 28.7% at 68 weeks on the 12 mg dose.
- TRANSCEND-T2D-1 (type 2 diabetes): Superior A1C reduction and weight loss versus placebo, with A1C reductions of up to 2.0% at 40 weeks.
- Cardiometabolic markers: Reductions in waist circumference, triglycerides, systolic blood pressure, non-HDL cholesterol, and hs-CRP were reported alongside weight outcomes.
Across the 12 mg dose, a striking 45.3% of participants lost more than 30% of their body weight. The broader TRIUMPH program has enrolled more than 5,800 participants, with additional readouts expected through the coming year.
Retatrutide vs Tirzepatide vs Semaglutide
The most common question researchers ask is how these three compounds differ. The short answer is the number of receptor pathways each one engages, and the effect size that follows.
| Compound | Receptor targets | Class | Peak weight reduction in trials* |
|---|---|---|---|
| Retatrutide | GIP + GLP-1 + glucagon | Triple agonist | ~30% (Phase 3) |
| Tirzepatide | GIP + GLP-1 | Dual agonist | ~21% (Phase 3) |
| Semaglutide | GLP-1 | Single agonist | ~15% (Phase 3) |
*Approximate peak averages from published clinical trial programs; figures vary by dose, duration, and study population.
The clear trend: adding pathways has been associated with larger effect sizes in trials. Retatrutide’s glucagon component is the differentiator, though it also means the compound behaves differently and warrants its own research protocols rather than assuming parity with GLP-1-only peptides.
Handling Retatrutide in the Lab: Reconstitution Basics
Retatrutide is supplied as a lyophilized powder and must be reconstituted before use in research. In a typical laboratory workflow, researchers add bacteriostatic water (BAC water) to the vial slowly, running it down the inside wall rather than directly onto the powder, and allow it to dissolve without agitation. Swirling gently is preferred over shaking. Our full peptide reconstitution guide walks through the steps in detail.
The exact concentration depends on the study design, and the volume of BAC water determines the concentration per unit. Because miscalculating this is one of the most common sources of error, most researchers verify their math with a dedicated tool such as the Panda Peptide dosage calculator before beginning. Reconstituted material is generally stored refrigerated and protected from light.
Again, this reflects laboratory handling only. Retatrutide is not approved for human use, and nothing here should be interpreted as human dosing guidance.
Sourcing Retatrutide Canada: What Researchers Should Check
Because retatrutide is unregulated as a research chemical, quality varies enormously between suppliers. When sourcing Retatrutide Canada research teams should prioritize:
- Third-party COA: An independent certificate of analysis (from a lab such as Janoshik) confirming identity and 99%+ purity for the specific batch.
- Domestic Canadian shipping: Material shipped from within Canada avoids customs delays and border-related degradation risk.
- Proper lyophilization and labeling: Clearly labeled vials designated for research use only.
- Batch traceability: The ability to match a vial to its test documentation.
Suppliers that publish per-batch testing, such as Anglo Peptides — a Canadian supplier of research-grade Retatrutide, which third-party tests every batch to 99%+ purity and ships domestically across Canada, give research teams the documentation trail they need for credible, repeatable results.
Frequently Asked Questions
What is retatrutide?
Retatrutide is an investigational triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors. It is being developed for obesity and type 2 diabetes research and is not yet approved for human use.
Is retatrutide available in Canada?
Not as an approved medication. Health Canada has not approved retatrutide for clinical use. For research, Retatrutide Canada suppliers offer it strictly as a research-use-only compound for laboratory applications.
Where can researchers buy retatrutide in Canada?
Canadian research teams source it from specialized peptide suppliers that provide third-party purity testing and domestic shipping. Look for a documented certificate of analysis confirming 99%+ purity for each batch.
Is retatrutide more effective than tirzepatide or semaglutide?
In clinical trials, retatrutide has shown larger average weight reductions (~30%) than tirzepatide (~21%) or semaglutide (~15%), which researchers attribute to its additional glucagon receptor activity. Direct head-to-head comparisons in humans remain limited.
How is retatrutide reconstituted for research?
It is supplied as a lyophilized powder and reconstituted with bacteriostatic water, added slowly and swirled gently. A peptide calculator is typically used to confirm concentration before use.
Disclaimer: This article is for educational and research reference only. Retatrutide is an investigational compound not approved for human consumption in Canada. All products referenced are intended strictly for laboratory research use. Nothing in this article constitutes medical advice.